Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society. It is estimated that more than 60 million people worldwide suffer from neurodegenerative diseases, with no currently approved disease-modifying therapies available.1‚2‚3 As modern therapeutic interventions increase life expectancy, the number of patients suffering from these diseases is expected to double every 20 years.1‚2 Global costs for treating these diseases are currently estimated at $818 billion and expected to grow to more than $1 trillion by 2030.1‚2‚3
Yumanity Therapeutics is advancing a new strategy in targeting the underlying protein pathology of neurodegenerative diseases, which allows the company to discover therapies that may modify the root cause of these neurodegenerative diseases rather than only addressing their symptoms. The company is currently focused on Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), with future applications across multiple additional protein misfolding diseases.
1. UBS, Alzheimer’s Report, July 2014; Industry Research
2. Alzheimer’s Disease International, World Alzheimer Report 2015
3. Parkinson’s Disease Foundation. http://parkinson.org/Understanding-Parkinsons/Causes-and-Statistics/Statistics